HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD

Henan Taloph Pharmaceutical Stock Co.,Ltd

600222

CNE0000010L8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
4.77 ^CNY	-0.21%		-5.92%	-22.19%

Apr. 25	Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on February 2, 2024.	CI

Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.

October 10, 2022

From July 14, 2022 to September 30, 2022, the company has repurchased 6,658,500 shares, representing 1.18% for CNY 34.95 million. With this, the company has completed the repurchase of 6,658,500 shares, representing 1.18% for CNY 34.95 million under the buyback announced on July 15, 2022.

Latest news about Henan Taloph Pharmaceutical Stock Co.,Ltd

Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on February 2, 2024.	Apr. 01	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd announces an Equity Buyback for CNY 60 million worth of its shares.	Feb. 01	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd authorizes a Buyback Plan.	Jan. 31	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Henan Taloph Pharma Receives 41 Million Yuan in Government Grants in Q3	23-10-09	MT
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Taloph Pharmaceutical Gets Nod to Amend License of Three Products	23-07-21	MT
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-07-13	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback announced on July 15, 2022, has closed with 14,523,100 shares, representing 2.57% for CNY 79.72 million.	23-07-12	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-07-03	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-06	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-03-31	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-01-03	CI
Henan Taloph Pharma Vice Chairman Resigns; Shares Slump 10%	22-12-19	MT
Tailong Health Industry Investment Co., Ltd announced that it expects to receive CNY 220 million in funding from Henan Taloph Pharmaceutical Stock Co.,Ltd	22-11-09	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	22-10-10	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd announces an Equity Buyback for CNY 80 million worth of its shares.	22-07-14	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd authorizes a Buyback Plan.	22-07-13	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd(SHSE:600222) added to Shanghai Stock Exchange Composite Index	22-05-09	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd(SHSE:600222) dropped from Shanghai Stock Exchange Composite Index	22-05-05	CI

Chart Henan Taloph Pharmaceutical Stock Co.,Ltd

Duration

Period

Chart Henan Taloph Pharmaceutical Stock Co.,Ltd

More charts

Company Profile

HENANTALOPHPHARMACEUTICALSTOCKCO., LTD is a China-based company principally engaged in the research and development, manufacture and sales of pharmaceuticals. The Company provides oral solutions, transfusion and tablets, which are applied in the treatment of cold, diabetes and virus infection. The Company's main products include Shuanghuanglian oral liquid products, double gold agents, Haberffine tablets and compound Yimu oral solutions, among others. The Company distributes its products mainly within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD	-22.19%	368M
ELI LILLY AND COMPANY	+38.67%	727B
NOVO NORDISK A/S	+30.57%	592B
JOHNSON & JOHNSON	-7.66%	347B
MERCK & CO., INC.	+15.49%	319B
ABBVIE INC.	-0.32%	274B
ASTRAZENECA PLC	+12.55%	238B
NOVARTIS AG	+6.65%	204B
ROCHE HOLDING AG	-6.09%	203B
PFIZER, INC.	-2.99%	160B